Jennison Associates
SYRE icon

Jennison Associates’s Spyre Therapeutics SYRE Stock Holding History

Jennison Associates’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.9M Buy
+303,180
New +$22.1M 0.02% 303
2019
Q2 		– Sell
-31,044
Closed -$6.25M – 676
2019
Q1 		$6.25M Sell
31,044
-23,028
-43% -$4.8M 0.01% 457
2018
Q4 		$10.1M Sell
54,072
-7,224
-12% -$1.53M 0.01% 434
2018
Q3 		$14.7M Buy
61,296
+278
+0.5% +$64.9K 0.01% 436
2018
Q2 		$16.1M Buy
61,018
+814
+1% +$200K 0.02% 428
2018
Q1 		$14.9M Buy
60,204
+4,466
+8% +$807K 0.01% 427
2017
Q4 		$7.54M Buy
55,738
+335
+0.6% +$41K 0.01% 479
2017
Q3 		$6.57M Sell
55,403
-464
-0.8% -$43.5K 0.01% 497
2017
Q2 		$5.36M Sell
55,867
-2,314
-4% -$320K 0.01% 505
2017
Q1 		$10.8M Buy
58,181
+352
+0.6% +$49.7K 0.01% 483
2016
Q4 		$6.29M Buy
57,829
+831
+1% +$121K 0.01% 502
2016
Q3 		$9.13M Buy
56,998
+1,475
+3% +$205K 0.01% 480
2016
Q2 		$6.69M Buy
+55,523
New +$10.6M 0.01% 491

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jennison Associates's SYRE Position: Q2 2026 in Review

Jennison Associates opened a new position in Spyre Therapeutics (SYRE) in Q2 2026: 303,180 shares worth $26.9M. The stake represents 0.02% of the portfolio and ranks #303 among its holdings. This is a return to the name: Jennison Associates previously reported a position in SYRE as recently as Q1 2019.

Jennison Associates first reported a position in SYRE in Q2 2016 and has held it in 13 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Jennison Associates held 303,180 shares of Spyre Therapeutics worth $26.9M as of Q2 2026.
  • Spyre Therapeutics was a new Jennison Associates position in Q2 2026.
  • Spyre Therapeutics made up 0.02% of Jennison Associates's portfolio in Q2 2026, its #303 holding.
  • Jennison Associates first reported a position in Spyre Therapeutics in Q2 2016 and has held it in 13 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Jennison Associates's 13F filing for Q2 2026, filed 3 Aug 2026.